Zidovudine phosphorylation after short-term and long-term therapy with zidovudine in patients infected with the human immunodeficiency virus*
- 23 August 1996
- journal article
- research article
- Published by Wiley in Clinical Pharmacology & Therapeutics
- Vol. 60 (2) , 168-176
- https://doi.org/10.1016/s0009-9236(96)90132-0
Abstract
Resistance of human immunodeficiency virus (HIV) to zidovudine (AZT) has been associated with mutations in the viral reverse transcriptase gene. However, recent studies suggest that host cellular factors such as a decreased thymidine kinase activity or an increased cellular P-glycoprotein expression may be important. This study compared concentrations of zidovudine monophosphate, zidovudine diphosphate, and zidovudine triphosphate with P-glycoprotein expression in peripheral blood mononuclear cells from patients receiving long-term (> 18 months) and short-term (< 2 months) zidovudine treatment. Ten subjects in the short-term group and 11 subjects in the long-term group with CD4 counts between 300 and 500 received a single oral dose of zidovudine (200 mg) after a 24-hour washout period. Blood samples were collected at 0, 1, 2, 4, and 6 hours. Intracellular nucleotide concentrations were measured by a combined HPLC-radioimmunoassay method, and P-glycoprotein expression was determined by fluorescence activated cell sorting (FACS) analysis with use of the monoclonal mouse antibody MRK-16. Zidovudine monophosphate was the predominant compound, accounting for 73.4% +/- 7.1% (SD) of the total phosphates in the long-term treatment group and 74.2% +/- 15.0% (SD) in the short-term group. Zidovudine diphosphate accounted for 13.3% +/- 3.3% (SD) in the long-term group and 12.5% +/- 6.6% (SD) in the short-term group. Zidovudine triphosphate accounted for 13.4% +/- 4.1% (SD) in the long-term group and 13.5% +/- 8.3% (SD) in the short-term group. Mean peak concentrations for the active zidovudine triphosphate were 0.04 +/- 0.02 (SD) pmol/10(6) cells in both groups. Comparison of the individual zidovudine phosphate concentrations and P-glycoprotein expression revealed no significant difference in the two patient populations. These data suggest that intracellular phosphorylation does not change over time and that zidovudine does not select for P-glycoprotein expressing cells.Keywords
This publication has 20 references indexed in Scilit:
- Quantification of zidovudine and individual zidovudine phosphates in peripheral blood mononuclear cells by a combined isocratic high performance liquid chromatography radioimmunoassay methodJournal of Pharmaceutical and Biomedical Analysis, 1996
- Zidovudine Induces the Expression of Cellular Resistance Affecting Its Antiviral ActivityAIDS Research and Human Retroviruses, 1994
- Zidovudine phosphorylation in HIV-infected patients and seronegative volunteersAIDS, 1994
- Pharmacokinetics of zidovudine phosphorylation in peripheral blood mononuclear cells from patients infected with human immunodeficiency virusAntimicrobial Agents and Chemotherapy, 1994
- Enzymatic assay for measurement of zidovudine triphosphate in peripheral blood mononuclear cellsAntimicrobial Agents and Chemotherapy, 1994
- Intracellular zidovudine (ZDV) and ZDV phosphates as measured by a validated combined high-pressure liquid chromatography-radioimmunoassay procedureAntimicrobial Agents and Chemotherapy, 1992
- Resistance of HIV-1 to AZT Might Also Involve the Cellular Expression of Multidrug Resistance P-GlycoproteinAIDS Research and Human Retroviruses, 1992
- Human immunodeficiency virus I-induced expression of P-glycoproteinBiochemical and Biophysical Research Communications, 1990
- Multiple Mutations in HIV-1 Reverse Transcriptase Confer High-Level Resistance to Zidovudine (AZT)Science, 1989
- HIV with Reduced Sensitivity to Zidovudine (AZT) Isolated During Prolonged TherapyScience, 1989